Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
The Lung Cancer Screening Market is predicted to reach US$ by 2030 from US$ 2.65 billion in 2021, and to grow at a CAGR of 7.7% between the forecast period 2022 to 2030.
The research report includes specific segments by Products/Type and by Application, by region (country). This study provides information about the sales and revenue of each segment during the historic and forecasted period from 2022 to 2030. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
This report also provides information on the prevalent market dynamics such as market drivers and restraints and future growth opportunities anticipated within the forecast period. The report includes competitive landscape of the top players operating in the market for the base year 2021. The company profiles section of the report studies the position of the major market players based on considerations such as business profile, product/service portfolio, trailing annual revenues, and recent strategies.
Major segmentation covered in this report is as follows:
By Cancer Type (Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC)), by Test Type (Biopsy, Imaging and Biomarker Test), by End-user (Cancer Research Institute, Diagnostic Imaging Centers, Hospital Associated Labs, Independent Diagnostic Laboratories)
By Region
North America, Europe, Asia Pacific, and the Rest of the World
Major market players covered in this study are
Qiagen N.V., Thermo Fisher Scientific Inc., Sanofi S.A., Agilent Technologies, Roche Diagnostics, and FUJIFILM Holdings Corporation, Medtronic plc, CANON MEDICAL SYSTEMS CORPORATION, Siemens Healthineers AG, and Koninklijke Philips N.V. among others
1. INTRODUCTION
1. Market Ecosystem
2. Timeline Under Consideration
1. Historical Years - 2020
2. Base Year - 2021
3. Forecasted Years - 2022 to 2030
3. Currency Used in the Report
2. RESEARCH METHODOLOGY
1. Research Approach
2. Data Collection Methodology
3. Data Sources
1. Secondary Sources
2. Primary Sources
4. Market Estimation Approach
1. Bottom Up
2. Top Down
5. Market Forecasting Model
6. Limitations and Assumptions
3. PREMIUM INSIGHTS
1. Current Market Trend (COVID-19 Perspective)
2. Key Players & Competitive Positioning (2021)
4. MARKET DYNAMICS
1. Drivers
2. Restraints
3. Opportunities
5. GLOBAL Lung Cancer Screening - ANALYSIS & FORECAST, BY PRODUCT
Product 1, Product 2
6. GLOBAL Lung Cancer Screening - ANALYSIS & FORECAST, BY TYPE
Type 1, Type 2
1. GLOBAL Lung Cancer Screening - ANALYSIS & FORECAST, BY END USER
End User 1, End User 2
2. GLOBAL Lung Cancer Screening - ANALYSIS & FORECAST, BY REGION
North America Lung Cancer Screening
1. North America Lung Cancer Screening , by Country
1. US
2. Canada
1. North America Lung Cancer Screening , by Product
2. North America Lung Cancer Screening , by Type
3. North America Lung Cancer Screening , by Gender
4. North America Lung Cancer Screening , by Sales Channel
3. Europe Lung Cancer Screening
1. Europe Lung Cancer Screening , by Country/Region
1. Germany
2. UK
3. France
4. Rest of Europe
2. Europe Lung Cancer Screening , by Product
3. Europe Lung Cancer Screening , by Type
4. Europe Lung Cancer Screening , by Gender
5. Europe Lung Cancer Screening , by Sales Channel
4. Asia Pacific Lung Cancer Screening
1. Asia Pacific Lung Cancer Screening , by Country/Region
1. China
2. Japan
3. India
4. Rest of Asia Pacific
2. Asia Pacific Lung Cancer Screening , by product
3. Asia Pacific Lung Cancer Screening , by Type
4. Asia Pacific Lung Cancer Screening , by Gender
5. Asia Pacific Lung Cancer Screening , by Sales Channel
5. Rest of the World Lung Cancer Screening
1. Rest of the World Lung Cancer Screening , by Region
1. Latin America
2. Middle East & Africa
2. Rest of the World Lung Cancer Screening , by Product
3. Rest of the World Lung Cancer Screening , by Type
4. Rest of the World Lung Cancer Screening , by Gender
5. Rest of the World Lung Cancer Screening , by Sales Channel
2. COMPANY PROFILES
Company 1, Company 62
Request Sample 
Request Discount 
Inquire Before Buy
